Jennison Associates’s Rein Therapeutics RNTX Stock Holding History

Jennison Associates’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-91,648	Closed	-$1.23M	–	682
2019 Q3	$1.23M	Sell	91,648 -10,265	-10%	-$142K	﹤0.01%	525
2019 Q2	$1.47M	Sell	101,913 -100	-0.1%	-$2.62K	﹤0.01%	517
2019 Q1	$3.83M	Buy	102,013 +88,404	+650%	+$2.75M	﹤0.01%	476
2018 Q4	$229K	Sell	13,609 -1,576	-10%	-$63.3K	﹤0.01%	637
2018 Q3	$835K	Buy	15,185 +120	+0.8%	+$8.07K	﹤0.01%	567
2018 Q2	$1.63M	Buy	15,065 +190	+1%	+$21.5K	﹤0.01%	542
2018 Q1	$2.42M	Buy	14,875 +2,263	+18%	+$403K	﹤0.01%	504
2017 Q4	$2.66M	Buy	12,612 +145	+1%	+$34.8K	﹤0.01%	518
2017 Q3	$3.34M	Sell	12,467 -33	-0.3%	-$8.28K	﹤0.01%	514
2017 Q2	$2.79M	Buy	+12,500	New	+$2.74M	﹤0.01%	526

Other funds holding RNTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPFA

Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return

IWAG

Integer Wealth Advisors Group Cartersville, Georgia $184M AUM 62.15% 1-Year Est. Return

PCS

Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return

Jennison Associates's RNTX Position: Q4 2019 in Review

Jennison Associates sold out of Rein Therapeutics (RNTX) in Q4 2019, closing a stake of 91,648 shares — an estimated $1.23M sold.

Jennison Associates first reported a position in RNTX in Q2 2017 and held it in 10 quarters. The position peaked at $3.83M in Q1 2019. 17 funds tracked by Wall St. Rank hold RNTX as of Q4 2019.

Jennison Associates reported no remaining Rein Therapeutics position as of Q4 2019 after selling out during the quarter.
Jennison Associates sold 91,648 Rein Therapeutics shares in Q4 2019, an estimated $1.23M.
Jennison Associates first reported a position in Rein Therapeutics in Q2 2017 and held it in 10 quarters.
Jennison Associates's Rein Therapeutics position peaked at $3.83M in Q1 2019.
17 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2019.

Based on Jennison Associates's 13F filing for Q4 2019, filed 7 Feb 2020.